Cleveland Clinic | Strategic Alliance Partners

Cleveland Clinic Cancer Institute provides complete cancer care enhanced by innovative basic, clinical and translational research. It offers the most effective techniques to achieve long-term survival and improve patients’ quality of life. Cleveland Clinic Cancer Institute’s more than 800 physicians, researchers, nurses and technicians care for thousands of patients each year and provide access to a wide range of clinical trials. Cleveland Clinic Cancer Institute has a global presence, uniting clinicians based in our Cancer Institute, Cleveland Clinic’s other patient-centered institutes, our regional hospitals and health centers, and our operations in Florida, London and Abu Dhabi. Cleveland Clinic is a nonprofit, multi-specialty academic medical center with more than 5,000 staff physicians and researchers who integrate outpatient and hospital care with research and education for better patient outcomes and experience. Cleveland Clinic is a trusted healthcare leader. We’re recognized in the U.S. and throughout the world for our expertise and care.

Be sure to tune into our Cancer Advances podcast where we explore the latest innovative research and clinical advances in the field of oncology. Listen now!

Connect with us:

Latest from Cleveland Clinic

Dr. Dreicer on Next-Generation AR Therapies in CRPC

April 14, 2014

Video

Robert Dreicer, MD, MS, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer.

Dr. Dreicer on Combining Agents With Immunotherapies

March 27, 2014

Video

Robert Dreicer, MD, MS, discusses combining and sequencing agents with immunotherapies for the treatment of prostate cancer.

Failed Studies Provide Clues in Renal Cell Carcinoma

December 23, 2013

Article

The mTOR inhibitor temsirolimus has limited utility in combination with frontline bevacizumab and as a second-line single agent for patients with metastatic renal cell carcinoma

Fine Print of Budget Deal Doesn't Bode Well for SGR Overhaul

December 19, 2013

Article

The tiny "raise" touted in the latest temporary fix to Medicare's Sustainable Growth Rate, which was wrapped inside the bipartisan budget deal headed to President Obama's desk, is anything but good news for oncologists.

Dr. Budd on Prior Trastuzumab and Paclitaxel Regimens

September 17, 2013

Video

G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, Professor, Hematology & Medical Oncology, Case Western Reserve University, discusses prior treatment with trastuzumab and the effect on two regimens of paclitaxel.

In Historic Vote, ODAC Suggests Approval of Neoadjuvant Pertuzumab Regimen

September 12, 2013

Article

The FDA's Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.

Dr. Budd Discusses Paclitaxel Regimens in Breast Cancer

June 25, 2013

Video

G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, discusses the background and results of the S0221 trial in breast cancer.

Dr. Dreicer on an Alternate Sunitinib Schedule in mRCC

April 01, 2013

Video

Robert Dreicer, MD, MS, from the Cleveland Clinic in Ohio, discusses a 2-weeks-on and 1-week-off (2/1) schedule of sunitinib for patients with metastatic renal cell carcinoma.